The Value of DNA Content in Predicting the Prognosis of Thyroid Carcinoma in an Endemic Iodine Deficiency Region

References

• Franssila K. O. Prognosis in thryoid carcinoma. Cancer, 1975, 36: 1138-46.
   PubMed Web of Science ®Google Scholar
• Mazaferri E. L., Young R. L., Oertel J. E., Kemmerer W. T., Page C. P. Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine, 1977, 56: 171-196.
   PubMed Web of Science ®Google Scholar
• Staunton M. D., Greening W. P. Treatment of thyroid cancer in 293 patients. Br J Surg, 1976, 63: 253-8.
   PubMed Web of Science ®Google Scholar
• Tezelman S., Clark O. H. Current management of thyroid cancer. Adv Surg, 1995, 28: 191-221.
   PubMedGoogle Scholar
• Hay I. D., Grant C. S., Taylor W. F., McConahey V. M. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma : a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery, 1987, 102: 1088-95.
   PubMed Web of Science ®Google Scholar
• Cady B., Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery, 1988, 104: 947-53.
   PubMed Web of Science ®Google Scholar
• Shah J. P., Loree T. R., Dharker D., Strong E. W., Bagg C., Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg, 1992, 164: 658-64.
   PubMed Web of Science ®Google Scholar
• Hay I. D., Bergstralh E. J., Goellner J. R., Ebersold J. R., Grant C. S. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system. Surgery, 1993, 114: 1050-8.
   PubMed Web of Science ®Google Scholar
• Pasieka J. L., Zedenius J., Auer G., Grimelius L., Hoog A., Lundell G., Wallin G., Backdahl M. Addition of nuclear DNA content to the AMES-risk group classification for papillary thyroid cancer. Surgery, 1992, 112: 1154-60.
   PubMed Web of Science ®Google Scholar
• Cohn K., Backdahl M., Forsslund B. M., Auer G., Lundell G., Löwhagen T., Tallroth E., Willems J. S., Zetterberg A., Granberg P. O. Prognostic value of of nuclear DNA content in papillary thyroid carcinoma. World J Surg, 1984, 8: 474-80.
   PubMed Web of Science ®Google Scholar
• Backdahl M., Carstensen J., Auer G., Tallroth E. Statistical evaluation of the value of nuclear DNA content in papillary, follicular and medullary thyroid tumors. World J Surg, 1986, 10: 974-80.
   PubMed Web of Science ®Google Scholar
• Backdahl M., Auer G., Forsslund G., Granberg P. O., Hamberger B., Lundell G., Löwhagen T., Zetterberg A. Prognostic value of nuclear DNA content in follicular thyroid tumours. Acta Chir Scand, 1986, 152: 1-7.
   PubMedGoogle Scholar
• Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Methods for analysis of cellular DNA content of paraffin-embedded pathological material using flowcytometry. J Histochem Cytochem, 1983, 31: 1333-5.
   PubMed Web of Science ®Google Scholar
• Cody H. S., Shah J. P. Locally invasive, well-differentiated thyroid cancer. 22 years’ experience at Memorial Sloan-Kettering Cancer Center. Am J Surg, 1981, 142, 480-3.
   PubMed Web of Science ®Google Scholar
• Wanebo H. J., Andrews W., Kaiser D. L. Thyroid cancer: Some basic considerations. Am J Surg, 1981, 142: 474-8.
   PubMed Web of Science ®Google Scholar
• Backdahl M., Cohn K., Auer G., Forsslund G., Granberg P. O., Lundell G., Lowhagen T., Willems J. S., Zetterberg A. Comparison of nuclear DNA content in primary and metastatic papillary thyroid carcinoma. Cancer Res, 1985, 45: 2890-4.
   PubMed Web of Science ®Google Scholar
• Cady B., Rossi R., Silverman M., Wool M. Further evidence of the validity of risk group definition in differentiated thyroid carcinoma. Surgery, 1985, 98: 1171-8.
   PubMed Web of Science ®Google Scholar
• Rossi R. L., Cady B., Silverman M. L., Wool M. S., Homer T. A. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg, 1986, 10: 612-22.
   PubMed Web of Science ®Google Scholar
• Buckwalter J. A., Thomas C. G. Selection of surgical treatment for well differentiated thyroid carcinomas. Ann Surg, 1972, 176: 565-78.
   PubMed Web of Science ®Google Scholar
• Clark O. H. Total thyroidectomy. The treatment of choice for patients with differentiated thyroid cancer. Ann Surg, 1982, 196: 361-70.
   PubMed Web of Science ®Google Scholar
• Grossman R. F., Tezelman S., Clark O. H. Thyroid cancer: The case for total thyroidectomy revisited. Head and Neck Cancer, Vol. III, (Eds. J. T. Johnson and M. S. Didolkar) Elsevier Science Publishers, 1993, 879-87.
   Google Scholar
• Grant C. S., Hay I. D., Gough I. R., Bergstralh E. J., Goellner J. P., McConahey W. M. Local recurrence in papillary thyroid carcinoma: Is extent of surgical resection important ? Surgery, 1988, 104: 954-62.
   PubMed Web of Science ®Google Scholar
• Cohn K. H., Backdahl M., Forsslund G., Auer G., Zetterberg A., Lundell G., Granberg P. O., Löwhagen T., Willems J. S., Cady B. Biologic considerations and operative strategy in papillary thyroid carcinoma: Arguments against routine performance of total thyroidectomy. Surgery, 1984, 96: 957-68.
   PubMed Web of Science ®Google Scholar
• Flint A., Davenport R. D., Lloyd R. V., Beckwith A. L., Thompson N. W. Cytophotometric measurements of Hurthle cell tumors of the thyroid gland. Cancer, 1988, 61: 110-3.
   PubMed Web of Science ®Google Scholar
• Schark C., Fulton N., Yashiro T., Stanislav G., Jacoby R., Straus II F. H., Dytch R., Bibbo M. The value of measurements of RAS oncogenes and nuclear DNA analysis in the diagnosis of Hurthle ccll tumors of the thyroid. World J Surg, 1992, 16: 745-52.
   PubMed Web of Science ®Google Scholar
• Wallin G., Backdahl M., Lundell G., Auer G., Löwhagen T. Nuclear DNA content and prognosis in Hurthle cell tumours of the thyroid gland. Acta Chir Scand, 1988, 154: 501-4.
   PubMedGoogle Scholar
• Ryan J. J., Hay I. D., Grant C. S., Rainwater L. M., Farrow G. M., Goellner J. R. Flow cytometric DNA measurements in benign and malignant Hurthle cell tumors of the thyroid. World J Surg, 1988, 12: 482-87.
   PubMed Web of Science ®Google Scholar
• Camargo R. S., Scaffiri A. G., Castro de Tolosa E. M., Ferreira E. A. B. DNA image cytometric analysis of differentiated thyroid adenocarcinoma specimens. Am J Surg, 1992, 164: 640-5.
   PubMed Web of Science ®Google Scholar
• Bergholm U., Adami H. O., Auer G., Bergstrom R., Backdahl M., Grimelius L., Hansson G., Ljungberg O., Wilander E., Group SMS. Histopathologic and nuclear DNA content as prognostic factors-in medullary thyroid carcinoma : a nationwide study in Sweden. Cancer, 1989, 64 : 135-42.
   PubMed Web of Science ®Google Scholar
• El-Naggar A. K., Ordonez N. G., McLemore D., Schultz P., Hickey R. C., Samaan N. Clinicopathologic and flowcytometric DNA study of medullary thyroid carcinoma. Surgery, 1990, 108: 981-5.
   PubMed Web of Science ®Google Scholar
• Tangen K. O., Lindmo T., Sabrinho-Simones M., Johannessen J. U. A flowcytometric DNA analysis of medullary thyroid carcinoma. Am J Clin Pathol, 1983, 79: 172-7.
   PubMed Web of Science ®Google Scholar
• Pyke C. M., Hay I. D., Goellner J. R., Bergstralh E. J., Van Heerden J. A., Grant C. S. Prognostic significance of calcitonin immunoreactivity, amyloid satining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery, 1991, 68: 324-30.
   Google Scholar
• Joensuu H., Klemi J. P. Comparison of DNA content in primary and metastatic differentiated thyroid carcinoma. Am J Clin Pathol, 1988, 89: 35-40.
   PubMed Web of Science ®Google Scholar
• Hanneqoin P., Liehn J. C., Delisle M. J. Multifactorial analysis of survival in thyroid cancer: pitfalls of applying the results of published studies to another population. Cancer, 1986, 58: 1749-55.
   PubMed Web of Science ®Google Scholar